ISEV Meeting (International Society of Extracellular Vesicles)

描述(申请人提供)：外体(微囊泡、转录体)是30-150 nm的囊泡，含有蛋白质、信使核糖核酸、微小核糖核酸和来源于起始细胞的核糖核酸。Exo/MCV被分解成生物体液(血浆、血清、脊髓液、尿液)，并可从这些体液中提纯。此R13应用程序支持将在马萨诸塞州总医院(与MGH学院联合)和位于马萨诸塞州波士顿的公园广场酒店和会议中心举行的第二届ISEV(国际细胞外小泡协会)国际会议。2013年4月16日至20日。这次会议将使美国临床医生(来自波士顿医疗和生物技术社区)将ISEV的550名基础科学家的工作转化为临床护理。会议将强调微囊泡(MCV)、外切体(EXO)、转录本在呈递病毒和细菌抗原、细胞-细胞mRNA的相互作用以及mcRNA和蛋白质的相互作用以及免疫调节剂、凝血成分和肿瘤特异性蛋白质和RNA突变的呈递中的临床作用。将举行CME认可的教育日和全体会议，以补充三个平行的口头会议。ISEV 2013会议和支持会议的R13将接待750-1000名与会者，并强调定义MCV/EXO颗粒的共识标准、关于制备和分离技术的协议以及标准化标本生物库；为支持肿瘤学、传染病和免疫学中的生物标记物验证研究的联盟奠定基础。没有其他会议能提供ISEV波士顿2013会议的范围和参与度。国家卫生研究院主任办公室(伊丽莎白·怀尔德)已经确定了非常感兴趣的EXO/MCV研究，并将规范性存储库和RNA研究作为优先事项，将在会议上讨论。这次会议提供了一个机会，可以转移ISEV的欧洲重点，扩大与美国和加拿大调查人员的互动。一个著名的国际小组将与波士顿地区的研究人员一起，形成96个口头演示文稿和270个主题分组的虚拟网络海报的焦点。教育日和全体会议将被记录下来，并通过网络广播，为医学生、相关领域的研究人员以及代表人数不足的少数群体和妇女提供服务。四个旅行奖学金将支持这些少数民族。会议中心符合ADA标准。

DESCRIPTION (provided by applicant): Exosomes (Microvesicles, transcriptomes) are 30-150nM vesicles containing proteins, mRNA, miRNA, and RNA derived from the cell of origin. The Exo/MCV aresecreted into biofluids (plasma, sera, spinal fluid, urine) and can be purified from these fluids. This R13 application supports the Second International Meeting of ISEV (International Society of Extracellular Vesicles) to be held at the Massachusetts General Hospital (in conjunction with The MGH Academy) and the Park Plaza Hotel and Conference Center in Boston, MA. April 16-20, 2013. The meeting will bring American clinicians (from the Boston medical and bio-technology communities) to translate to clinical care the work of the 550 basic scientists of ISEV. The meeting will emphasize the clinical roles of microvesicles (MCV), exosomes (EXO), transcriptomes in presentation of viral and bacterial antigens, interactions of cell-cell mRNA, as well as mcRNA and protein interactions and presentation of immune-regulators, coagulation components and tumor specific protein and RNA mutations. A CME accredited Educational Day and plenary sessions complementing three parallel oral sessions will occur. The ISEV 2013 meeting and the R13 that supports it, will host 750-1000 attendees and emphasize consensus standards by which to define MCV/EXO particles, agreements on preparative and isolation techniques and normative specimen biorepositories; set the basis for consortia that support biomarker validation studies in oncology, infectious diseases, and immunology. There exists no other meeting that offers the scope and participation of ISEV Boston 2013. The NIH Director's office (Elizabeth Wilder) has identified EXO/MCV studies of great interest and made normative repositories and RNA studies a priority which will be addressed at the meeting. The meeting provides an opportunity to shift the European focus of ISEV to broaden interaction with American and Canadian investigators. A distinguished international panel along with Boston area researchers will shape the focus of ninety-six oral presentations and 270 thematically- grouped 'virtual web posters'. The Educational Day and plenary sessions will be recorded and web - broadcast for service to medical students, researchers in allied fields and to serve under- represented minorities and women. Four traveling fellowships will support these minorities. The Conference Center is ADA compliant.